BrainsWay Appoints Dr. Colleen A. Hanlon as Vice President of Medical Affairs
Dr. Hanlon has Served as a Leader in Brain Stimulation Research for Nearly 20 YearsBURLINGTON, Mass. and JERUSALEM, Nov. 01,...
Clinical Trial
Axial Therapeutics CEO A. Stewart Campbell to Present at Microbiome Connect: USA 2022
WOBURN, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Axial Therapeutics, a clinical-stage biopharmaceutical company dedicated to the development of gut-targeted,...
Sema4|GeneDx Commends New Evidence-Based Guidelines from the National Society of Genetic Counselors Recommending Exome Sequencing as a First-Tier Genetic Test for Unexplained Epilepsies
Guideline adoption can help end the diagnostic odyssey experienced by many families STAMFORD, Conn., Oct. 31, 2022 (GLOBE NEWSWIRE) --...
Panbela Schedules Conference Call on, November 10, 2022, to Report 2022 Third Quarter Financial Results
MINNEAPOLIS, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for...
Scilex Holding Company (“Scilex”), a Sorrento Company (nearly 100% or over 99.9% majority-owned subsidiary of Sorrento Therapeutics, Inc.) (Nasdaq: SRNE, “Sorrento”), and Vickers Vantage Corp. I Announce Effectiveness of Registration Statement on Form S-4, Date of Vickers Vantage Extraordinary General Meeting to Approve Proposed Business Combination
SEC declared Effectiveness of Vickers’s registration statement on Form S-4Extraordinary General Meeting of Vickers Vantage Corp. I shareholders to approve...
Biofrontera Inc. Enters into Agreements to Purchase Options of Biofrontera AG
Sets company up to realize full commercial potential in fast growing U.S. marketSupports mutually beneficial interests between Biofrontera Inc and...
Albireo to Report Q3 2022 Financial Results on November 8, 2022
Conference call and webcast to be held at 4:30 pm ETBOSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc....
Allogene Overland Biopharm Completes Buildout of cGMP Manufacturing Facility in Shanghai to Support the Development of AlloCAR T™ Products in Asia
GMP Site Designed to Enable Potential Clinical and Commercial Production of AlloCAR T™ Products for Patients in Greater China, Taiwan,...
Mersana Therapeutics to Host Third Quarter 2022 Conference Call on November 7, 2022
CAMBRIDGE, Mass., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering...
KYS Vision Reports Clinical Trial Results of Its Remote Physiologic Monitoring System for Patients With Chronic Retinal Conditions
NEW YORK, Oct. 31, 2022 (GLOBE NEWSWIRE) -- KYS Vision, Inc., an eye care digital health company, today announced clinical...
FDA Accepts for Priority Review Ascendis Pharma’s NDA for TransCon™ PTH in Adult Patients with Hypoparathyroidism
- PDUFA target action date is April 30, 2023 - MAA submission to EMA on track for this quarter COPENHAGEN,...
Pharmazz Inc. Presents Positive Results of Phase III Clinical Trial Demonstrating Sovateltide’s Efficacy as a Treatment for Acute Cerebral Ischemic Stroke
Sovateltide produced statistically significant and clinically meaningful improvements in neurological outcomes in acute cerebral ischemic stroke patients and was well...
IO Biotech to Participate in the Jefferies London Healthcare Conference
NEW YORK, Oct. 31, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer...
Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending August 31, 2022
NEW HAVEN, Conn., Oct. 28, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a multi-asset...
CytoDyn Announces Voluntary Withdrawal of BLA for HIV-MDR Due to CRO Data Management Issues
Company to complete and submit responses to FDA clinical hold Continues to study leronlimab in other HIV-related, NASH, and oncology...
Akari Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification
NEW YORK and LONDON, Oct. 28, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing...
ARCA biopharma Announces Third Quarter 2022 Financial Results
Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic optionsWESTMINSTER,...
Y-mAbs Announces Outcome of FDA Advisory Committee Meeting on Omburtamab
NEW YORK, Oct. 28, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical...
Genmab Announces Submissions of Regulatory Applications for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL) and Diffuse Large B-Cell Lymphoma (DLBCL)
Media Release COPENHAGEN, Denmark; October 28, 2022 Genmab has Submitted Biologics License Application (BLA) to U.S. Food and Drug Administration...
Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD
Prescription Drug User Fee Act (PDUFA) goal date of August 29, 2023ISELIN, N.J., Oct. 28, 2022 (GLOBE NEWSWIRE) -- Outlook...